Why the study?
Does finerenone improve NT-proBNP levels compared to eplerenone in Japanese patients with worsening HFrEF and chronic kidney disease and/or diabetes?
Does finerenone improve NT-proBNP levels compared to eplerenone in Japanese patients with worsening HFrEF and chronic kidney disease and/or diabetes?
In a small phase 2b trial of Japanese patients with HFrEF and CKD/diabetes, finerenone was well tolerated and showed similar NT-proBNP reductions and potassium changes compared to eplerenone, though the study was underpowered for efficacy.
No takes yet. Share an insight, caveat, or question.
Comparable NT-proBNP reductions support finerenone tolerability versus eplerenone; extends phase 2 data in Japanese HFrEF patients but underpowered for efficacy.
Sato et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: